This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Legal opinion: Will Avadel be able to launch FT218 in a timely manner (YE21/early 2022)?

Ticker(s): AVDL, JAZZ

Who's the expert?

A lawyer with regulatory experience of these types of situations. Preferably someone who has been following this case.

Interview Questions
Q1.

Have you been following the current situation between AVDL and JAZZ ?

Do you have a clear belief as to whether FDA will ask AVDL to certify? 

What is that belief based on? 

Added By: user1a9v3vo5
Q2.

Other there many precedents that closely align to this case? What was the outcome? Please go through both claims brought by JAZZ as to why they believe FDA will force AVDL to certify, and their legitimacy.
  

Added By: user1a9v3vo5
Q3.

If AVDL is successful in gaining timely FDA approval, what options do JAZZ have to try and delay the launch of FT218? What do you believe the chances of JAZZ being successful may be in this scenario?

Added By: user1a9v3vo5

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.